StockData
Pelthos Therapeutics Inc. logo

Pelthos Therapeutics Inc. (PTHS) stock

PTHSNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 2/30
$6.84−0.31 (-4.34%)

Close on Nov 17, 2026Market cap $26.19MP/E –Yield –

Pelthos Therapeutics total assets

Total assets on the balance sheet at the end of each period.

Pelthos Therapeutics's total assets was $137.36M at Jun 30, 2026. For fiscal 2025 it was $130.40M, up 9425.0% from the year before.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$130.40M+9425.0%
FY2024Dec 31, 2024$1.37M+1320.3%
FY2023Dec 31, 2023$96.39K+75.0%
FY2022Dec 31, 2022$55.07K–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$137.36M+16592.7%
Q1 FY2026Mar 31, 2026$145.38M+15854.9%
Q4 FY2025Dec 31, 2025$130.40M+9425.0%
Q3 FY2025Sep 30, 2025$126.43M+5808.4%
Q2 FY2025Jun 30, 2025$822.85K-68.4%
Q1 FY2025Mar 31, 2025$911.18K-77.4%
Q4 FY2024Dec 31, 2024$1.37M+1320.3%
Q3 FY2024Sep 30, 2024$2.14M+3785.5%
Q2 FY2024Jun 30, 2024$2.60M–
Q1 FY2024Mar 31, 2024$4.03M–
Q4 FY2023Dec 31, 2023$96.39K–
Q4 FY2022Dec 31, 2022$55.07K–

More Pelthos Therapeutics figures

See a number that looks wrong?